HC Wainwright reiterated their buy rating on shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in a research note published on Monday, Marketbeat Ratings reports. HC Wainwright currently has a $1.50 price target on the stock, down from their previous price target of $4.50.
Separately, ValuEngine lowered Bio-Path Holdings from a sell rating to a strong sell rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $1.67.
Shares of Bio-Path Holdings (NASDAQ BPTH) traded down $0.01 during mid-day trading on Monday, reaching $0.29. The company’s stock had a trading volume of 236,400 shares, compared to its average volume of 394,712. Bio-Path Holdings has a 12 month low of $0.25 and a 12 month high of $1.38.
Bio-Path Holdings (NASDAQ:BPTH) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02). equities research analysts forecast that Bio-Path Holdings will post -0.08 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BPTH. Legal & General Group Plc grew its position in Bio-Path Holdings by 5,474.3% in the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock valued at $681,000 after acquiring an additional 1,741,978 shares in the last quarter. Sabby Management LLC grew its position in Bio-Path Holdings by 73.2% in the 2nd quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock valued at $462,000 after acquiring an additional 503,488 shares in the last quarter. Bank of New York Mellon Corp grew its position in Bio-Path Holdings by 1.7% in the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock valued at $257,000 after acquiring an additional 5,172 shares in the last quarter. Finally, HighTower Advisors LLC grew its position in Bio-Path Holdings by 0.3% in the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock valued at $492,000 after acquiring an additional 4,000 shares in the last quarter. 15.15% of the stock is owned by institutional investors.
Bio-Path Holdings Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with our FREE daily email newsletter.